A novel histone deacetylase inhibitor, Scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine

Breast Cancer Research and Treatment

Volumn 81, Issue 3, 2003, Pages 177-186

  Keen, Judith Clancy ^a   Yan, Lan ^a,b   Mack, Kelly M ^a,c   Pettit, Catherine ^a   Smith, Dawn ^a,d   Sharma, Dipali ^a   Davidson, Nancy E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MARYLAND EASTERN SHORE   (United States)

^d CENTOCOR INC   (United States)

Author keywords

5 aza 2 deoxycytidine; Breast cancer; DNA methylation; Estrogen receptor ; Histone acetylation; Scriptaid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; PROGESTERONE RECEPTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; DOSE RESPONSE; DRUG POTENTIATION; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE EXPRESSION; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT;

ACETYLATION; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BREAST NEOPLASMS; CELL DIVISION; DNA MODIFICATION METHYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXYLAMINES; INHIBITORY CONCENTRATION 50; QUINOLINES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0242330341     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026146524737     Document Type: Article

References (29)

1. Keen JC, Davidson NE: The biology of breast carcinoma. Cancer 97: 825-833, 2003
2. Asch BB, Barcellos-Hoff MH: Epigenetics and breast cancer. J Mammary Gland Biol Neoplasia 6: 151-152, 2001
3. Iwase H, Omoto Y, Iwata H, Toyama T, Hara Y, Ando Y, Ito Y, Fujii Y, Kobayashi S: DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br J Cancer 80: 1982-1986, 1999
4. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin, SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999
5. Baylin S, Bestor TH: Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1: 299-305, 2002
6. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002
7. Cheung W, Briggs S, Allis C: Acetylation and chromosomal functions. Curr Opin Cell Biol 12: 326-333, 2000
8. Bird A: Methylation talk between histones and DNA. Science 294: 2113-2115, 2001
9. Bird A, Wolffe A: Methylation-induced repression - belts, braces, and chromatin. Cell 99: 451-454, 1999
10. Bovenzi V, Momparler R: Antineoplastic action of 5-aza-2′- deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells. Cancer Chemother Pharmacol 48: 71-76, 2001
11. Zhu WG, Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Canc Agents 3: 187-199, 2003
12. Hebbes TR, Thorne AW, Crane-Robinson C: A direct link between core histone acetylation and transcriptionally active chromatin. Embo J 7: 1395-1402, 1988
13. Thaiagalingan S, Cheng K-H, Lee HJ, Mineva N, Thaiagalingan A, Ponte J: Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 983: 84-100, 2003
14. Ferguson AT, Lapidus R, Baylin S, Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283, 1995
15. Ottaviano Y, Issa J, Parl F, Smith H, Baylin S, Davidson N: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54: 2552-2555, 1994
16. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE: Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60: 6890-6894, 2000
17. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE: Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 61: 7025-7029, 2001
18. Gore S, Carducci M: Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp Opinion Invest Drugs 9: 2923-2934, 2000
19. Su GH, Sohn TA, Ryu B, Kern SE: A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 60: 3137-3142, 2000
20. Hahm H, Dunn V, Butash KA, Deveraux W, Woster P, Casero Jr R, Davidson NE: Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin Cancer Res 7: 391-399, 2001
21. Marks P, Rifkind R, Richon V, Breslow R, Miller T, Kelly W: Histone deacetylases and cancer:causes and therapies. Nature Rev: Cancer 1: 194-202, 2001
22. Vigushin D, Ali S, Pace P, Mirsaidi N, Ito K, Adcock I, Coombes R: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001
23. Iwase H: Molecular action of the estrogen receptor and hormone dependency in breast cancer. Breast Cancer 10: 89-96, 2003
24. Yan L, Yang X, Davidson NE: Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia 6: 183-192, 2001
25. Yan L, Nass SJ, Davidson NE: Effects of DMT 1 antisense oligonucleotide on steroid hormone expression in breast cancer cell lines. AACR 42: 844 (abstract #4556), 2001
26. Marks P, Richon V, Breslow R, Rifkind R: Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483, 2001
27. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000
28. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001
29. Jenuwein T, Allis CD: Translating the histone code. Science 293: 1074-1080, 2001